<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210525051398N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-05-30</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>The effect of probiotic use in children with functional constipation</public_title>
      <acronym></acronym>
      <scientific_title>The effect of probiotic use in children with functional constipation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56464</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Limited randomization with 75-person blocks is performed by the consulting pharmacist using a random number table of Random Allocation Software, Blinding description: This study is a double-blind clinical trial study performed on children with chronic functional constipation referred to the pediatric clinics of Shariati and Gharzi medical centers in Isfahan. All forms of medicine used are labeled the same and only labeled by the consulting pharmacist. First, the necessary explanations on how to implement the plan are provided to the parents, and then the informed consent form is completed and signed by the child's legal guardian. The personal details of the children participating in the project will be confidential. The required information will be collected by asking the parents and recorded in the relevant questionnaire. The forms are filled in anonymously and in coded form and the treating physician does not witness this process.</study_design>
      <phase>3</phase>
      <hc_freetext>Functional Constipation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The first group is dissolved Kidi Lactate probiotic powder in a dose of 1 sachet per day in water and 1 g / kg body weight of water-soluble polyethylene glycol powder is given daily for 2 weeks. At first, it is recommended to consume less food. High fat and dairy and recommend eating more fruits, vegetables and high fiber foods. Parents are also given the necessary training on using the toilet and encouraging their children to go to the toilet, and it is recommended that they exercise regularly and use the toilet after each meal. Intervention 2: Control group: 1 g / kg body weight of water-soluble polyethylene glycol powder is given daily for 2 weeks. Parents are also instructed in using the toilet and encouraging their children to go to the toilet, and it is recommended that they exercise regularly and use the toilet after each meal.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Pegah Kaveh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 5, Azar 17 Alley, Panje Azar St, Jaber Ansari Ave</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8138958638</zip>
        <telephone>+98 31 3433 1295</telephone>
        <email>pgh.kaveh@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Pegah Kaveh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 5, Azar 17 Alley, Panje Azar St, Jaberansari Ave</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8138958638</zip>
        <telephone>+98 31 3433 1295</telephone>
        <email>pgh.kaveh@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children with functional constipation
Between 2 to 15 years old</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>15 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Diseases of the large and small intestine
Sensitivity to polyethylene glycol
Intestinal obstruction
Kidney or heart failure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K59.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Constipation</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The first group is dissolved Kidi Lactate probiotic powder in a dose of 1 sachet per day in water and 1 g / kg body weight of water-soluble polyethylene glycol powder is given daily for 2 weeks. At first, it is recommended to consume less food. High fat and dairy and recommend eating more fruits, vegetables and high fiber foods. Parents are also given the necessary training on using the toilet and encouraging their children to go to the toilet, and it is recommended that they exercise regularly and use the toilet after each meal.</i_keyword>
      <i_keyword>Control group: 1 g / kg body weight of water-soluble polyethylene glycol powder is given daily for 2 weeks. Parents are also instructed in using the toilet and encouraging their children to go to the toilet, and it is recommended that they exercise regularly and use the toilet after each meal.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Number of bowel movements during one week. Timepoint: Number of bowel movements during one week at the beginning of the study (before the intervention) and 7 and 14 days after taking probiotics. Method of measurement: The required information is collected by asking the parents and recorded in the prepared questionnaire.</prim_outcome>
      <prim_outcome>Number of unwanted bowel movements during the day. Timepoint: Number of unwanted bowel movements during the day at the beginning of the study (before the intervention) and 7 and 14 days after taking probiotics. Method of measurement: The required information is collected by asking the parents and recorded in the prepared questionnaire.</prim_outcome>
      <prim_outcome>Number of painful bowel movements in a week. Timepoint: Number of painful bowel movements during one week at the beginning of the study (before the intervention) and 7 and 14 days after the start of probiotic use. Method of measurement: The required information is collected by asking the parents and recorded in the prepared questionnaire.</prim_outcome>
      <prim_outcome>The number of times abdominal pain occurs in a week. Timepoint: The frequency of abdominal pain during one week at the beginning of the study (before the intervention) and 7 and 14 days after taking probiotics. Method of measurement: The required information is collected by asking the parents and recorded in the prepared questionnaire.</prim_outcome>
      <prim_outcome>Determination and comparison of fecal consistency. Timepoint: Determination and comparison of fecal consistency at the beginning of the study (before the intervention) and 7 and 14 days after probiotic use. Method of measurement: The required information is collected by asking the parents and recorded in the prepared questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-09-30</approval_date>
        <contact_name>Ethics committee of Islamic Azad University - Shahrood Branch</contact_name>
        <contact_address>No. 5, Azar 17 Alley, Panje Azar St, Jaber Ansari Ave Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
